Wednesday, March 18, 2026 Please be aware that GA.3 (AGITG-AG0315OG): A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) trial has permanently closed. The letter of permanent trial closure/termination can be found in the members' area of the CCTG webpage here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closure Adults with histologically or cytologically confirmed advanced gastro-oesophageal Cancer (AGOC), with measurable metastatic or locally advanced disease, who have failed or were intolerant of 2 lines of prior anti-cancer therapy which have included a platinum & fluoropyrimidine analogue. The primary objective was OS in overall study population and in the Asian sub-population. Secondary objectives include PFS, objective tumour response rate (PR or CR); quality of life (QoL); safety (rates of adverse events). Primary Publication:Pavlakis, Nick;Shitara, Kohei;Sjoquist, Katrin;Martin, Andrew;Jaworski, Anthony;Tebbutt, Niall;Bang, Yung-Jue;Alcindor, Thierry;O'Callaghan, Chris;Strickland, Andrew;Young Rha, Sun; Lee, Keun-Wook;Kim, Jin-Soo;Bai, Li-Yuan;Hara, Hiroki;Oh, Do-Youn;Yip, Sonia;Zalcberg, John;Price, Tim;Simes, John;Goldstein, David INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer (ONLINE) Journal of Clinical Oncology Journal of Clinical Oncology:ONLINE, 2024 For more information please visit the CCTG GA3 members trial page.
